Across-the-board review on Omicron SARS-CoV-2 variant
- PMID: 39714724
- DOI: 10.1007/s10787-024-01627-4
Across-the-board review on Omicron SARS-CoV-2 variant
Abstract
Introduction: Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a cataclysmic pandemic. Several SARS-CoV-2 mutations have been found and reported since the COVID-19 pandemic began. After the Alpha, Beta, Gamma, and Delta variants, the Omicron (B.1.1.529) is the most recently emerged variant of concern (VOC), which has evolved as a result of a high number of mutations, particularly in the spike protein, raising concerns about its ability to evade pre-existing immunity acquired through vaccination or natural infection.
Methods: This is a review based on studies published from November 2021 to September 2024.
Result and discussions: The current article discusses the advent of the SARS-CoV-2 Omicron variant, its key characteristics and significant global health concerns, as well as measures for dealing with it in the context of the continuing COVID-19 pandemic. Various mutations in Omicron have been discussed that contribute to increased transmissibility and immune evasion from vaccine-induced or natural immunity acquired after infection. To understand the similarities and differences between different VOCs and Omicron, we conducted a comparative investigation.
Conclusion: Strengthening research, improving genomic surveillance and tracking, developing highly effective vaccines and immunotherapies, designing appropriate strategies, action plans, and future preparedness plans must all be prioritized and implemented quickly at global levels to mitigate the high global health concerns associated with the emergence of this new Omicron variant well before it causes large-scale COVID-19 outbreaks.
Keywords: B.1.1.529; COVID-19; Omicron; SARS-CoV-2; Variant of interest; Variants of concern.
© 2024. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Conflict of interest statement
Declarations. Conflict of interest: The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Similar articles
-
The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.Front Med (Lausanne). 2022 May 20;9:849217. doi: 10.3389/fmed.2022.849217. eCollection 2022. Front Med (Lausanne). 2022. PMID: 35669924 Free PMC article. Review.
-
Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review.Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8019-8022. doi: 10.26355/eurrev_202112_27653. Eur Rev Med Pharmacol Sci. 2021. PMID: 34982466 Review.
-
Characterization of the novel SARS-CoV-2 Omicron (B.1.1.529) variant of concern and its global perspective.J Med Virol. 2022 Apr;94(4):1738-1744. doi: 10.1002/jmv.27524. Epub 2022 Jan 11. J Med Virol. 2022. PMID: 34905235
-
Update on SARS-CoV-2 Omicron Variant of Concern and Its Peculiar Mutational Profile.Microbiol Spectr. 2022 Apr 27;10(2):e0273221. doi: 10.1128/spectrum.02732-21. Epub 2022 Mar 30. Microbiol Spectr. 2022. PMID: 35352942 Free PMC article.
-
Omicron: What Makes the Latest SARS-CoV-2 Variant of Concern So Concerning?J Virol. 2022 Mar 23;96(6):e0207721. doi: 10.1128/jvi.02077-21. Epub 2022 Mar 23. J Virol. 2022. PMID: 35225672 Free PMC article. Review.
References
-
- Abdullah F. Tshwane District Omicron Variant Patient Profile - Early Features. South African Medical Research Council. 4 December 2021. Available from: https://www.samrc.ac.za/news/tshwane-district-omicron-variant-patient-pr... . Accessed 1 Jan 2022
-
- Antony S. Omicron Wave Sees South Africa’s Weekly Excess Deaths Almost Double. Bloomberg. 8 December 2021. Available from: https://www.bnnbloomberg.ca/omicron-wave-sees-south-africa-s-weekly-exce... . Accessed 3 Jan 2022
-
- Assessment of the further emergence and potential impact of the SARS-CoV-2 Omicron variant of concern in the context of ongoing transmission of the Delta variant of concern in the EU/EEA, 18th update (Technical report). Stockholm: European Centre for Disease Prevention and Control. 15 December 2021. Available from: https://www.ecdc.europa.eu/en/publications-data/covid-19-assessment-furt... . Accessed 12 Jan 2022
-
- BA.1 Lineage Report. Scripps Research. 19 December 2021. Accessed 29 Dec 2021
-
- Burki TK (2021) Omicron variant and booster COVID-19 vaccines. Lancet Respir Med. https://doi.org/10.1016/S2213-2600(21)00559-2 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
Supplementary concepts
LinkOut - more resources
Medical
Miscellaneous